Figure 1: Experimental procedure

(modified; according to Tronche *et al*., 2010)






Figure 2



*; **and *** : $p < 0.05$; $p < 0.01$ and $p < 0.001$ respectively *vs.* carrier-carrier;

+ and +++ : $p < 0.05$ and $p < 0.001$ *vs.* donepezil.


Figure 3



*; **and *** : $p < 0.05$; $p < 0.01$ and $p < 0.001$ respectively *vs.* carrier-carrier;

+ and +++ : $p < 0.05$ and $p < 0.001$ *vs.* donepezil.

<u>Figure 4:</u> Study of the EPSPs induced by electrical stimulation in alert mice after administration of rivastigmine (0.03 mg/kg p.o., curve with squares); of 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3*H*-[1,3]oxazino[6,5-*g*]-[1,2,3]benzotriazine-4,9-dione (Compound S, 3 mg/kg p.o., curve with triangles); of the association of the two compounds in the same doses (curve with crosses); and of the carrier (curve with diamonds)



* : $p < 0.05$: rivastigmine + Compound S versus carrier;
¢ : $p < 0.05$ rivastigmine versus carrier;
¤ : $p < 0.05$ Compound S versus carrier.

- Carrier
- 0.03 mg/kg of rivastigmine
- 3 mg/kg of compound S
- Combination: 3 mg/kg of compound S + 0.03mg/kg of rivastigmine